DLBCL-话题@MedSci

#DLBCL#

51篇内容 | 1437人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1360517, encodeId=19fb136051eae, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, objectType=article, longId=211832, objectId=fc31211832f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31211832f6, replyNumber=0, likeNumber=51, createdTime=2021-05-27, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31211832f6, moduleTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31211832f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360516, encodeId=f44a136051646, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, objectType=article, longId=211283, objectId=6e722112837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e722112837b, replyNumber=0, likeNumber=39, createdTime=2021-05-15, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e722112837b, moduleTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e722112837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360515, encodeId=fc251360515ac, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！, objectType=article, longId=210699, objectId=0bbd21069923, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bbd21069923, replyNumber=0, likeNumber=57, createdTime=2021-05-02, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bbd21069923, moduleTitle=J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bbd21069923)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360514, encodeId=6614136051437, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性, objectType=article, longId=210513, objectId=1f42210513fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f42210513fc, replyNumber=0, likeNumber=0, createdTime=2021-04-28, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f42210513fc, moduleTitle=J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f42210513fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360513, encodeId=85e01360513be, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, objectType=article, longId=209158, objectId=40ec209158b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ec209158b9, replyNumber=0, likeNumber=43, createdTime=2021-03-31, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ec209158b9, moduleTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ec209158b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360512, encodeId=9d711360512af, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, objectType=article, longId=207552, objectId=b86b20e552cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b86b20e552cf, replyNumber=0, likeNumber=50, createdTime=2021-02-26, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b86b20e552cf, moduleTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b86b20e552cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360511, encodeId=b80c1360511fb, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=J Clin Oncol：简化版老年患者评估量表在DLBCL老年患者中的应用, objectType=article, longId=207491, objectId=1c6c20e49130, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c6c20e49130, replyNumber=0, likeNumber=49, createdTime=2021-02-24, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c6c20e49130, moduleTitle=J Clin Oncol：简化版老年患者评估量表在DLBCL老年患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c6c20e49130)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360510, encodeId=9f25136051070, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=J Clin Oncol：R-CHOP方案+来那度胺可进一步改善新确诊DLBCL患者预后, objectType=article, longId=207043, objectId=91d820e04381, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91d820e04381, replyNumber=0, likeNumber=54, createdTime=2021-02-12, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91d820e04381, moduleTitle=J Clin Oncol：R-CHOP方案+来那度胺可进一步改善新确诊DLBCL患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91d820e04381)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360509, encodeId=61481360509a5, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？, objectType=article, longId=206361, objectId=420e206361f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=420e206361f1, replyNumber=0, likeNumber=40, createdTime=2021-01-30, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=420e206361f1, moduleTitle=J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=420e206361f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360508, encodeId=48c213605081d, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, objectType=article, longId=206207, objectId=df2920620e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2920620e11, replyNumber=0, likeNumber=42, createdTime=2021-01-26, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2920620e11, moduleTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2920620e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360507, encodeId=aaee136050eb1, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood：阿托珠单抗用于初治的aaIPI≥1的DLBCL患者的疗效不优于利妥昔单抗, objectType=article, longId=204528, objectId=c65320452846, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c65320452846, replyNumber=0, likeNumber=43, createdTime=2020-12-17, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c65320452846, moduleTitle=Blood：阿托珠单抗用于初治的aaIPI≥1的DLBCL患者的疗效不优于利妥昔单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c65320452846)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360506, encodeId=a99f13605064f, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？, objectType=article, longId=203318, objectId=3485203318ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3485203318ee, replyNumber=0, likeNumber=31, createdTime=2020-11-14, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3485203318ee, moduleTitle=Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3485203318ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360505, encodeId=02e81360505cf, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制, objectType=article, longId=203317, objectId=5a9020331ec1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a9020331ec1, replyNumber=0, likeNumber=41, createdTime=2020-11-14, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a9020331ec1, moduleTitle=Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a9020331ec1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360504, encodeId=1a9613605048a, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Ann Hematol：异基因干细胞移植可有效治疗DLBCL, objectType=article, longId=201788, objectId=4e94201e8841, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e94201e8841, replyNumber=0, likeNumber=40, createdTime=2020-10-08, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e94201e8841, moduleTitle=Ann Hematol：异基因干细胞移植可有效治疗DLBCL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e94201e8841)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360503, encodeId=4a7e136050329, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood：piRNA-30473通过调节m6A RNA甲基化促进DLBCL发生和预后不良, objectType=article, longId=201201, objectId=2be1201201f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be1201201f5, replyNumber=0, likeNumber=37, createdTime=2020-09-27, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be1201201f5, moduleTitle=Blood：piRNA-30473通过调节m6A RNA甲基化促进DLBCL发生和预后不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be1201201f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360502, encodeId=c0cb13605021b, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood：PET-CT指导性巩固放疗对晚期DLBCL患者长期预后的影响, objectType=article, longId=200532, objectId=ac7a200532c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac7a200532c2, replyNumber=0, likeNumber=32, createdTime=2020-09-12, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac7a200532c2, moduleTitle=Blood：PET-CT指导性巩固放疗对晚期DLBCL患者长期预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac7a200532c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360501, encodeId=94891360501a3, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后, objectType=article, longId=198980, objectId=03fb1989807e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03fb1989807e, replyNumber=0, likeNumber=46, createdTime=2020-08-09, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03fb1989807e, moduleTitle=Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03fb1989807e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360500, encodeId=6ecb13605005a, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood：根据基因表达亚群将DLBCL分成新的亚型, objectType=article, longId=187423, objectId=574e18e423b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574e18e423b2, replyNumber=0, likeNumber=46, createdTime=2020-02-06, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574e18e423b2, moduleTitle=Blood：根据基因表达亚群将DLBCL分成新的亚型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=574e18e423b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360499, encodeId=b4101360499cd, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性, objectType=article, longId=187353, objectId=19ef18e35330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19ef18e35330, replyNumber=0, likeNumber=43, createdTime=2020-02-05, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19ef18e35330, moduleTitle=Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19ef18e35330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360498, encodeId=0bf41360498ce, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood：高起始总代谢瘤体积有助于鉴别超高危险的DLBCL人群, objectType=article, longId=187114, objectId=435d18e1145d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=435d18e1145d, replyNumber=0, likeNumber=38, createdTime=2020-02-03, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=435d18e1145d, moduleTitle=Blood：高起始总代谢瘤体积有助于鉴别超高危险的DLBCL人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=435d18e1145d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

DLBCL

2020-05-29

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型

2021-05-27

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！

2021-05-15

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！

2021-05-02

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性

2021-04-28

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤

2021-03-31

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS

2021-02-26

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

J Clin Oncol：简化版老年患者评估量表在DLBCL老年患者中的应用

2021-02-24

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

J Clin Oncol：R-CHOP方案+来那度胺可进一步改善新确诊DLBCL患者预后

2021-02-12

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？

2021-01-30

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）

2021-01-26

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Blood：阿托珠单抗用于初治的aaIPI≥1的DLBCL患者的疗效不优于利妥昔单抗

2020-12-17

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？

2020-11-14

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制

2020-11-14

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Ann Hematol：异基因干细胞移植可有效治疗DLBCL

2020-10-08

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Blood：piRNA-30473通过调节m6A RNA甲基化促进DLBCL发生和预后不良

2020-09-27

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Blood：PET-CT指导性巩固放疗对晚期DLBCL患者长期预后的影响

2020-09-12

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后

2020-08-09

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Blood：根据基因表达亚群将DLBCL分成新的亚型

2020-02-06

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性

2020-02-05

cathymary (审核中...)

前往app查看评论内容

#DLBCL#

Blood：高起始总代谢瘤体积有助于鉴别超高危险的DLBCL人群

2020-02-03

科室
- - 订阅+
  - 更多科室
工具
服务